HomeCompareHBMHF vs GBDC

HBMHF vs GBDC: Dividend Comparison 2026

HBMHF yields 128.21% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $9.18M in total portfolio value· pulled ahead in Year 10
10 years
HBMHF
HBMHF
● Live price
128.21%
Share price
$1.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.60M
Annual income
$4,575,129.27
Full HBMHF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — HBMHF vs GBDC

📍 GBDC pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBMHFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBMHF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBMHF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBMHF
Annual income on $10K today (after 15% tax)
$10,897.44/yr
After 10yr DRIP, annual income (after tax)
$3,888,859.88/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $10,042,014.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBMHF + GBDC for your $10,000?

HBMHF: 50%GBDC: 50%
100% GBDC50/50100% HBMHF
Portfolio after 10yr
$16.19M
Annual income
$10,482,196.33/yr
Blended yield
64.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

HBMHF
No analyst data
Altman Z
8.0
Piotroski
7/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBMHF buys
0
GBDC buys
0
No recent congressional trades found for HBMHF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBMHFGBDC
Forward yield128.21%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$11.60M$20.78M
Annual income after 10y$4,575,129.27$16,389,263.41
Total dividends collected$10.60M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: HBMHF vs GBDC ($10,000, DRIP)

YearHBMHF PortfolioHBMHF Income/yrGBDC PortfolioGBDC Income/yrGap
1$23,521$12,820.51$12,490$1,790.28+$11.0KHBMHF
2$53,349$28,181.78$16,522$3,157.73+$36.8KHBMHF
3$116,823$59,739.54$23,578$5,898.68+$93.2KHBMHF
4$247,259$122,259.11$37,115$11,886.75+$210.1KHBMHF
5$506,405$241,837.18$66,136$26,423.57+$440.3KHBMHF
6$1,004,750$462,896.88$137,257$66,491.44+$867.5KHBMHF
7$1,933,425$858,342.70$341,734$194,868.54+$1.59MHBMHF
8$3,612,406$1,543,641.03$1,050,788$685,133.02+$2.56MHBMHF
9$6,560,727$2,695,452.74$4,099,314$2,974,971.01+$2.46MHBMHF
10← crossover$11,595,107$4,575,129.27$20,775,530$16,389,263.41$9.18MGBDC

HBMHF vs GBDC: Complete Analysis 2026

HBMHFStock

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Full HBMHF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this HBMHF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBMHF vs SCHDHBMHF vs JEPIHBMHF vs OHBMHF vs KOHBMHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.